Clinical trials
Functional Magnetic Resonance Imaging clinical trials
Below are recruiting functional magnetic resonance imaging clinical trials, each written for real people, not researchers. We’re tracking 275 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05691491RecruitingPhase 1/Phase 2
Temozolomide plus M1774 for advanced metastatic cancers
This Phase 1/2 trial tests a combination of temozolomide and M1774 to see how safe it is and whether it can help shrink advanced cancers that have spread. It focuses on certain tumor types and specific biomarker results, and it may be an option if standard treatments have been tried or aren’t possible.
Irvine, CaliforniaAges 18 years+ - NCT05711615RecruitingPhase 1
Low-dose doxorubicin plus peposertib for advanced sarcoma
This Phase 1 trial tests a low dose of a common chemotherapy (liposomal doxorubicin) together with an anti-cancer drug called peposertib. It’s for people with advanced sarcoma that can’t be cured, aiming to find a safe dosing plan and see how well the treatment might work.
Los Angeles, CaliforniaAges 18 years+ - NCT05733000RecruitingPhase 2
CPI-613 plus hydroxychloroquine with chemo for advanced solid tumors
This trial tests a drug called CPI-613 (devimistat) combined with hydroxychloroquine along with either 5-fluorouracil or gemcitabine chemo. It’s for people with advanced cancers that have stopped responding to standard treatments, aiming to shrink tumors and slow cancer growth.
Chicago, IllinoisAges 18 years+ - NCT05746325Recruiting
Tumor-pulse device for spinal cancer fluid spread
This trial tests whether Tumor Treating Fields (a non-surgical device that delivers treatment signals to cancer cells through the scalp/skin) can help people whose breast or lung cancer has spread into the fluid around the spine and brain. It focuses on people who have cancer cells found in spinal fluid and can safely use the device most of the day.
Jacksonville, FloridaAges 18 years+ - NCT05756569RecruitingPhase 2
Enfortumab plus pembrolizumab for advanced bladder cancer variants
This trial studies enfortumab vedotin plus pembrolizumab (immunotherapy) for people with advanced bladder cancer that has a “variant” or non-urothelial subtype. It aims to shrink tumors and improve outcomes when standard options have not worked or are no longer enough.
Atlanta, GeorgiaAges 18 years+ - NCT05770531RecruitingPhase 2
Blood test guides chemo changes for metastatic breast cancer
This Phase 2 study uses a blood test that looks for “circulating tumor DNA” to help decide if standard chemotherapy should be changed. It aims to see whether this approach improves how well treatment works for certain metastatic (stage IV) breast cancers.
Nashville, TennesseeAges 18 years+ - NCT05791448RecruitingPhase 1
AU409 for advanced liver cancers or liver-spread tumors
This Phase 1 trial studies AU409, a new medicine, for advanced primary liver cancers or other solid tumors mainly in the liver. It aims to find a safe dose and see how well the treatment works for people whose usual options have not worked or are not available.
Los Angeles, CaliforniaAges 18 years+ - NCT05803382RecruitingPhase 1
Adding a new drug to capecitabine for metastatic colorectal cancer
This Phase 1 study tests a new anti-cancer drug (ZEN003694) added to the usual chemotherapy capecitabine. It is for adults with colorectal cancer (and possibly other cancers) that has spread or cannot be removed and has continued despite prior standard treatment.
Irvine, CaliforniaAges 18 years+ - NCT05806515RecruitingPhase 2
Carboplatin before surgery for high-risk BRCA prostate cancer
This trial tests giving the chemotherapy drug carboplatin before surgery to treat people with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene change. The goal is to shrink or control the cancer before an operation and improve outcomes.
Anchorage, AlaskaAges 18 years+ - NCT05847569RecruitingPhase 2
Testing alternating doses of belantamab for hard-to-treat myeloma
This Phase 2 trial tests whether alternating doses and schedules of belantamab mafodotin can help people with multiple myeloma that has returned or kept progressing after several prior treatments. You may be eligible if your disease has specific measurable signs and your blood counts and organs are healthy enough for study treatment.
Jacksonville, FloridaAges 18 years+ - NCT05859334RecruitingPhase 2
Erdafitinib for brain tumors that came back or worsened
This Phase 2 study tests erdafitinib, a targeted anti-cancer medicine, for certain brain cancers that have returned or progressed after standard treatment. It may help if your tumor has a specific genetic change (FGFR-TACC fusion) that this drug is designed to attack.
Aurora, ColoradoAges 18 years+ - NCT05890352RecruitingPhase 2
Add new medicines to standard treatment for returning lymphoma
This Phase 2 study tests whether adding tafasitamab, lenalidomide, tazemetostat, and zanubrutinib (along with standard lymphoma treatment) can improve outcomes in people whose large B-cell lymphoma has returned or not responded. It may help control disease more effectively and improve response duration for eligible patients.
Tucson, ArizonaAges 18 years+ - NCT05896839RecruitingPhase 1/Phase 2
Immunotherapy with prednisone and sirolimus for transplant skin cancer
This early-phase study tests whether adding immunotherapy (nivolumab and ipilimumab) to prednisone and sirolimus can control advanced skin cancers in people with kidney transplants. It aims to see how well the treatment works and how safe it is for transplant recipients.
La Jolla, CaliforniaAges 18 years+ - NCT05919108RecruitingPhase 2
Neratinib before surgery for HER2-mutated invasive lobular breast cancer
This Phase 2 trial tests neratinib given before surgery to treat stage I–III invasive lobular breast cancer that has a specific HER2 mutation and is hormone-receptor positive. It may help shrink the tumor and improve control of cancer before and after surgery.
Atlanta, GeorgiaAges 18 years+ - NCT05934188Recruiting
Study how gut signals relate to brain aging and diseases
This study looks at how the gut may influence the brain in normal aging and conditions like Alzheimer’s, Parkinson’s, and multiple sclerosis. It may help researchers understand new ways to measure or treat these brain changes over time.
Venice-Lido, VeniceAges 20–90 - NCT06022939RecruitingPhase 3
Comparing chemo plus stem cell transplant to chemo alone for AL amyloidosis
This study tests whether adding a stem cell transplant to standard chemotherapy (Dara-VCD) works better than chemotherapy alone for people newly diagnosed with AL amyloidosis. It aims to find the best way to control the disease and improve outcomes.
Goodyear, ArizonaAges 18 years+ - NCT06029270RecruitingPhase 2
Adding relatlimab to standard immunotherapy for nasopharyngeal cancer
This trial tests whether adding a new drug called relatlimab to the usual immunotherapy (nivolumab) helps people with nasopharyngeal cancer that has returned or spread. You will get standard chemotherapy plus nivolumab first, then if it works, you may be randomly assigned to get nivolumab alone or with relatlimab.
Dublin, CaliforniaAges 18 years+ - NCT06031688RecruitingPhase 2
Targeted treatment for lung cancer with a MET gene change
This trial tests a targeted drug for advanced non-small cell lung cancer that has a specific genetic change called MET exon 14 skipping. It aims to see if the drug can shrink tumors or slow the cancer's growth, and may help people who have or haven't had prior treatment.
Daphne, AlabamaAges 18 minutes+ - NCT06057909Recruiting
Brain function study in Lewy body and Alzheimer's disease
This study looks at how brain function changes over time in people with Lewy body disease or Alzheimer's. Researchers will use memory tests, MRI scans, and EEG (a painless brain-wave recording) to track these changes, and you will need a family member or friend to help report on your daily life.
Scottsdale, ArizonaAges 50–95 - NCT06058663RecruitingPhase 1
Radiation and immunotherapy for advanced bile duct cancer
This trial tests combining a targeted radiation treatment (radioembolization) with two immunotherapy drugs (tremelimumab and durvalumab) for people with advanced intrahepatic cholangiocarcinoma that cannot be removed by surgery. It aims to shrink tumors and control cancer spread to lymph nodes or one other organ.
Jacksonville, FloridaAges 18 years+ - NCT06086704RecruitingPhase 2
PET/MRI scan for PR-positive breast cancer before surgery
This trial tests a new PET/MRI scan (using a special tracer called 18F-FFNP) to see how it images progesterone-receptor-positive breast cancer before surgery. You would get the scan and then have your planned surgery.
Madison, WisconsinAges 18 years+ - NCT06110572RecruitingPhase 1/Phase 2
Total body irradiation with immunotherapy for extensive SCLC
This trial adds total body irradiation (a low dose of radiation to the whole body) to standard atezolizumab (immunotherapy) plus chemotherapy for people with extensive-stage small cell lung cancer. The goal is to see if the radiation helps the immunotherapy work better.
Nashville, TennesseeAges 18 years+ - NCT06116682RecruitingPhase 2
Targeted treatment for MET-positive advanced lung cancer
This trial tests a targeted therapy for people with advanced non-small cell lung cancer whose tumors have extra copies of the MET gene. It's for those whose cancer has progressed after at least one prior treatment.
Jonesboro, ArkansasAges 18 years+ - NCT06130280RecruitingPhase 2
MRI-guided radiation for liver tumors from colorectal cancer
This trial tests a single, high-dose radiation treatment (SBRT) guided by MRI for people with colorectal cancer that has spread to the liver. The goal is to see if this precise, one-time treatment can effectively control liver tumors while protecting nearby organs.
Basking Ridge, New JerseyAges 18 years+
Hear when a new Functional Magnetic Resonance Imaging trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for functional magnetic resonance imaging?
- Yes. Clin2 currently lists 275 recruiting functional magnetic resonance imaging studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a functional magnetic resonance imaging trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a functional magnetic resonance imaging trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.